Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,004 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS. Tan RYC, et al. Among authors: park yh. J Natl Compr Canc Netw. 2024 May 14:1-9. doi: 10.6004/jnccn.2023.7121. Online ahead of print. J Natl Compr Canc Netw. 2024. PMID: 38744306
Analysis of retinal and choroidal microvascular changes using optical coherence tomography and optical coherence tomography angiography in patients with acute leukemia.
Lee JH, Kim JJ, Hong SY, Kim GH, Kim JY, Kim RY, Kim M, Park YG, Kim YJ, Cho BS, Lee S, Kim HJ, Park YH. Lee JH, et al. Among authors: park yh. Graefes Arch Clin Exp Ophthalmol. 2024 May 7. doi: 10.1007/s00417-024-06504-y. Online ahead of print. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38713398
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Fehm T, et al. Among authors: park yh. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. Lancet Oncol. 2024. PMID: 38697155 Free article. Clinical Trial.
3,004 results